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Abstract High affinity nidogen binding oflaminin-1 (chain com- 
position allgl3'l) has been previously mapped to a single EGF- 
like motif ylI I I4 of its y1 chain. Two more isoforms, laminin-5 
(¢v3~3y2) and laminin-7 (¢~3~2y1), show low and high binding 
activity, respectively, indicating that the y2 chain is of low affin- 
ity. This was confirmed by recombinant production of the homol- 
ogous EGF-like motif `/2III4 of the `/2 chain, which has a 
100,000-fold lower binding activity than -/11114. The crucial hep- 
tapeptide binding sequence Asn-lle-Asp-Pro-Asn-Ala-Val of 
-/11114 is modified in -/21114 by replacing both the central Asn and 
Val by Ser. Changing these replacements to Asn and Val by 
site-directed mutagenesis enhanced the activity of -/21114 to a 
level which was only 5-fold lower than that of -/11114. Despite 
their high sequence identity (77%) motifs -/11114 and -/21114 were 
also shown to differ considerably in immunological epitopes. This 
indicates distinctly different functions for laminins which differ 
in the -/chain isoform. 
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I. Introduction 
The 150 kDa glycoprotein idogen seems to play a central 
role in basement membrane assembly due to its binding poten- 
tial for several laminins, collagen IV, perlecan and the fibulins 
[1, 2]. The ability of nidogen to form ternary or higher-order 
complexes with these ligands has led to the concept hat it 
mediates the connection between etworks formed separately 
by laminins and collagen IV and thus stabilizes the supramol- 
ecular organization of such extracellular matrices [3, 4]. This 
was recently underscored in studies with antibodies which 
block the nidogen binding site of laminin [5] and retard kidney 
tubulogenesis and lung branching when added to embryonic 
organ cultures [6]. Nidogen is therefore one of the mediators 
in these developmental processes, which depend on mesenchy- 
mal-epithelial interactions [7]. It is also now becoming increas- 
ingly clear that in many of these developmental nd repair 
processes nidogen is contributed by the mesenchyme while cer- 
tain laminin isoforms originate from the epithelium [8]. The 
place of their first interaction is then the extracellular space, 
which explains the inhibitory effects of antibodies. 
*Corresponding author. Fax: (49) (89) 8578 2422. 
Abbreviations: PCR, polymerase chain reaction; IC50, inhibitory capac- 
ity, 50%. 
The nidogen binding site of laminin-1 has been mapped in 
proteolytic and recombinant s udies to a single EGF-like motif, 
yl l I I4, in the short arm of its 7/1 chain [5, 9]. Such motifs consist 
of 50~60 residues and are predicted to form four disulfide- 
bonded loops (a to d) based on their homology to EGF and 
cysteine patterns [10]. Subsequent studies demonstrated that 
two non-contiguous regions in loops a and c of y 11114 contrib- 
ute to high affinity binding (Kd = 0.5nM) in a cooperative man- 
ner [11]. The contact region in loop a has been restricted to a 
heptapeptide s quence while that of loop c is not yet completely 
mapped. Studies with synthetic peptides and site-directed mu- 
tants also showed that only a few residues are crucial for bind- 
ing and predicted that the laminin 2/2 chain should have only 
a low binding activity. 
The laminins represent a large protein family consisting of 
various ~, fl, 7/ chain heterotrimers with seven different 
isoforms identified so far [2, 12, 13]. Laminin-1, laminin-2 and 
laminin-4 (~lf l ly l ;  ~2fllyl; ~2f12yl) share the yl  chain and 
high affinity nidogen binding [3, 14, 15]. Laminin-5, previously 
referred to as kalinin/nicein, however, has the chain composi- 
tion c~3f13T2 and all chains show truncated short arm structures 
[16, 17]. It is found primarily in anchoring filaments of squame- 
ous epithelium where it is connected to laminin-6 (ct3fllyl) by 
disulfide bonds [18, 19]. Sequence analysis of the y2 chain 
demonstrated an EGF-like motif y2III4 which showed 77% 
identity to the nidogen binding motif y l I I I4 [20, 21]. In the 
present study we have analyzed nidogen binding of laminin-5 
and laminin-7 (ct3fl2yl) and of recombinant EGF-like repeats 
possibly involved in interactions. This demonstrated that only 
two residues in 7/2III4 of laminin-5 are responsible for low 
affinity. 
2. Experimental 
2.1. Sources of proteins 
Human laminin-5 was purified by antibody affinity chromatography 
from SCC25 culture medium [16]. Laminin-7 was obtained from human 
amnion (M.F. Champliaud, G.P. Lunstrum, M.P. Marinkovich, P. 
Rouselle, T. Nishiyama, D.R. Keene, R.E. Burgeson, in preparation). 
Recombinant mouse nidogen and laminin-1 fragment P1 were those 
used previously [3]. Recombinant motif 2/11114 was purified from the 
culture medium of stably transfected 293 cell clones as described [5]. 
The same chromatographic procedures were used to purify ~'2III4 and 
the ~,21114 mutant. SDS-polyacrylamide g l electrophoresis on a 16% 
gel made from a stock solution of 40% acrylamide, 1.3% bis-acrylamide 
followed standard protocols. 
2.2. Expression vectors and cell tramfections 
The cDNA clone Ka166c, corresponding to a partial sequence of 
human laminin ~,2 chain [21], was used to generate fragments for ex- 
pression vectors by polymerase chain reaction (PCR) with Vent polym- 
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erase (New England Biolabs) according to the supplier's instruction. 
The following oligonucleotide primers, some with underlined muta- 
tions, were synthesized: primer 1,5'-GATCCCTAGCGCCCTGTCA- 
ATGCAACA; primer 2,5'-GATCCTCGAGCTAAGCTCGACACT- 
TGTCTG; primer 3,5'-CAACAACAATGTGGATCCCAATGC- 
CGTTGGGAATTGTGACCGGC; primer-4, 5'-TGGG_ATCCACAT- 
TGTTG; primer 5,5'-GTAACCATTATAAGCTGC; and primer 6,5'- 
CCTTTCTCTCCACAGGTG. 
Primers 1 and 2 were used to construct the vector encoding the ),2III4 
motif (position 516-572 of y2) and also introduced a 5' NheI site and 
a 3' stop codon and Xhol site for connecting the construct to the BM-40 
signal peptide as previously described [5]. The 0.21 kb PCR product was 
purified, cut with NheI and XhoI and cloned into the PCis vector [22] 
which was modified with the signal peptide [5] to yield the expression 
vector pCMVT2III4. Residues Ser 526 and Ser 528 encoded in this expres- 
sion vector were mutated to Asn and Val, respectively, by a strategy 
applied previously [11]. Two products were generated by PCR using 
primers 4 and 6 and primers 3 and 5 and contained the mutations and 
a common overlapping neutral BamHI site for identification of the 
correct clones. The purified products were fused by one cycle of denatu- 
ration, annealing and extension. The correct fusion product (0.4 kb) 
was amplified by PCR with primers 5and 6, cut with HindlII and Xhol 
to 0.3 kb and cloned into corresponding sites of the episomal expression 
vector pCEP4 (Invitrogen), which possesses the hygromycin B resis- 
tance gene. The correct structure of the inserts was verified by DNA 
sequencing and restriction mapping. 
Vector pCMVy2III4 and plasmid pSV2pac were used to cotransfect 
the embryonic kidney cell line 293 (American Type Culture Collection) 
and to produce stably transfected clones and serum-free medium for 
purification of ),2III4 [23]. Human kidney cells which constitutively 
express the EBNA-1 protein from Epstein-Barr virus (293-EBNA cells; 
lnvitrogen) were grown according to the manufacturer's protocol. 
Transfection of the cells with pCEP4 plasmids [23] was followed by 
selection of resistant cells in the presence of 300/lg/ml medium of 
hygromycin B (Calbiochem). These cells were then grown to confluency 
and used to obtain serum-free culture medium. 
2.3. Binding assays and immunological methods 
A radioligand assay consisting of soluble recombinant idogen and 
~25I-labelled laminin-1 fragment P 1 was used in competition tests for the 
determination f relative affinities based on ICs0 (inhibitory capacity, 
50%) values [3, 9, 14]. Direct binding was analyzed in solid-phase assays 
using one ligand in plastic-immobilized form and an antibody detection 
system for the soluble ligand [24]. A rabbit was immunized with three 
0.2 mg doses of 72II14 by subcutaneous injections with complete 
Freunds' adjuvant at intervals of 3~1 weeks. ELISA and immunoblot- 
ting followed routine protocols. 
3. Results 
A radiological competition assay involving nidogen and 125I- 
labelled fragment P1 from mouse laminin-1 (chain composition 
~l f l ly l )  was used to examine nidogen binding affinity of two 
novel laminin isoforms (Fig. 1). The interaction ofnidogen and 
fragment P1 could be completely blocked by fragment P1 and 
its recombinant subfragment y lIII4, to which the entire activity 
has been attributed [5], with ICs0 values in the range 0.06- 
0.1nM. Human laminin-7 (ct3f1271) had a similar activity 
(ICs0 = 0.15 nM) while laminin-5 (0t3f1372) had an activity too 
low to be measured (ICs0 > 20 nM). A more than 100-fold 
difference between laminin-5 and fragment P1 was also ob- 
served in a direct nidogen binding assay [3, 24] using both 
laminins in the immobilized form (data not shown). 
Domain III of the y2 chain of laminin-5 possesses an EGF-  
like motif )'2III4, with a high sequence identity (77%) to the 
nidogen-binding motif y l I I I4  of the 71 chain [20, 21]. There 
are, however, several substitutions in a heptapeptide s quence 
of disulfide-bonded loop a (Fig. 2) which has been shown to be 
crucial for binding [11]. We therefore prepared T2III4 in recom- 
O) 
t -  
. I  
"0 
t,- 
° 1  
rn  
100 
80 
60 
40 
20 
0 
• A-A_A_A 
I I I I I 
10-2 10-1 10 0 101 10 2 
Inhibitor (nM) 
° \ r3  
\ 
[] 
\ 
[] 
\ 
[] 
I I 
103 104 
Fig. 1. Inhibition of radioligand binding between idogen and laminin- 
1 fragment P1 by human laminins and recombinant EGF-like motifs. 
Inhibitors used were mouse fragment P1 (o) and its ylIIl4 motif (e), 
human laminin-5 (A) and laminin-7 (A), the y21II4 motif of human 
laminin y2 chain ([3) and mutant 2"21114 (,) with Ser 526 to Asn and Ser 528 
to Val substitutions. 
binant form in an eukaryotic expression system which was 
previously shown to yield correctly folded EGF-like domains 
[5]. The purified fragment showed an electrophoretic mobility 
similar to that of y l I I I4  indicating a molecular mass of about 
7 kDa (Fig. 3A). With an ICs0 = 13 pM, however, its affinity 
for nidogen was 100,000-fold lower than y l I I I4  (Fig. 1). This 
affinity was even distinctly lower than that of synthetic hep- 
tapeptide NIDPNAV (ICs0 = 0.4/IM) designed according to a 
y l I I I4  sequence [l 1]. We therfore prepared a 72III4 double 
mutant where Ser 526 and Ser 52s within the heptapeptide binding 
region were converted to Asn and Val, respectively, corre- 
sponding to the substitutions found in ~'lIII4 (Fig. 2). The 
recombinant mutant showed a comparable electrophoretic mo- 
bility to y2III4 (Fig. 3B) but had a much higher nidogen affinity 
(ICs0 = 0.4 nM), approaching that of y l I I I4  (Fig. 1). Thus a 
very restricted change in the sequence is responsible for a con- 
siderable improvement in binding. 
It was also of interest to compare immunological epitopes of 
y2III4 with those of yl I I I4. An antiserum raised against 
y2III4, showed a strong reaction with y2III4 in ELISA but a 
500-fold lower reaction with laminin fragment P1 or a recombi- 
nant fragment possessing the yl I I I4  motif. Furthermore, in 
Western blots the antiserum bound primarily to a 105 kDa 
band of reduced laminin-5 and more weakly to a 155 kDa band 
(Fig. 3B). Since these two bands correspond to the precursor 
and processed forms of the y2 chain [17], this demonstrates lack 
of cross-reaction with the c~3 and f13 chains of laminin-5. 
4. Discussion 
The obvious importance of the laminin-nidogen interaction 
for basement membrane assembly, as indicated from in vitro 
and in vivo studies [1, 6], has raised the intriguing question of 
whether all laminin isoforms known so far [2, 12, 13] possess 
the same binding potential. A single binding site of high affinity 
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Fig. 2. Amino acid sequence of human laminin EGF-Iike motif ?'2H14 (top) and comparison with the homologous nidogen binding motif ?'1II14 
(bottom) of mouse laminin. Only the substitutions are shown for ?' 11114. The sequences correspond topositions 516-571 of the ?'2 chain ([21]; including 
signal peptide) and to positions 792-847 of the ?' 1 chain [25]. The recombinant ?'21114 product possesses an additional APLA sequence derived from 
the signal peptide [5]. Loops a to d are indicated underneath e sequence. The shaded area in ?'21114 loop a indicates arelated heptapeptide sequence 
involved in nidogen binding of ?'11114 [11]. Two substitutions in this region which are crucial for binding are shown in bold letters. 
(Kd = 0.5 nM) has been localized to the short arm structure of 
laminin-1 (ctlfllz1)contributed by the ZI chain [5, 9]. The same 
high affinity was previously shown for laminin-2 and laminin-4 
[15] and in the present study for laminin-7. These laminins hare 
the Z1 chain but differ in their a and/orfl chains, indicating that 
chain composition is unimportant for nidogen binding, in 
agreement with the topological separation of the binding site 
from the other chains as shown by electron microscopy [26]. 
Additionally, the data predict hat laminin-3 (~ lf12 Z 1) and lam- 
inin-6 (a3fllz1), which have not yet been studied, will also have 
a high affinity for nidogen. 
Only a very low nidogen binding activity could be demon- 
strated for laminin-5 (~3f1372), apparently due to the replace- 
ment of the 7/1 by the 2/2 chain. It is very likely caused by the 
change of the nidogen binding EGF-like motif ? l I I I4  [5] to the 
homologous motif Z2III4, which show 77% sequence identity 
(Fig. 2). This identity is still remarkably higher than the 52-55% 
identity observed between other EGF-like motifs in domains 
III and V of both y chains [20], suggesting a common ancestral 
motif for ZIIII4 and Z2III4, which considerably changed its 
functional properties upon further divergence. Laminin-5 is a 
major component of anchoring filaments in squamous epithe- 
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Fig. 3. SDS-gel electrophoresis of purified recombinant EGF-like mo- 
tifs (A) and immunoblot reaction with an antiserum against ?'21114 (B). 
Samples in A were ?'11114 (lane 1), ?'2III4 (lane 2) and ?'21114 mutant 
(lane 3). The blotted protein in B was laminin-5. The asterisk marks an 
additional faint reaction at about 155 kDa. All samples were reduced 
with 2-mercaptoethanol. Positions of molecular mass markers (in kDa) 
are indicated in the margins. 
lium [19] and mutations in the f13 and 7/2 chains are associated 
with blistering skin diseases [27-29]. Further data showed the 
formation of a disulfide-bonded complex between laminin-5 
and laminin-6 [19], which could explain how such structures are 
connected to the lamina densa of basement membranes, for 
example by nidogen-mediated binding to laminin-6. 
The nidogen binding site of mouse 71III4 has been previ- 
ously mapped to two restricted regions in the disulfide-bonded 
loops a and c by chimeric recombinant products, site-directed 
mutagenesis and synthetic peptides [11]. Cooperation between 
the two regions is required to result in high binding affinity 
although a heptapeptide s quence in loop a (see Fig. 2) makes 
the most critical contribution. Human Z2III4 differs in the 
heptapeptide r gion by three substitutions and in studies with 
synthetic 71III4 variants, two of them, Asn to Ser and Val to 
Ser, were shown to inactivate binding [11]. This has now been 
clearly demonstrated bysimultaneous site-directed mutation of 
both Ser in 72III4 back to the Z1 chain substitutions, producing 
a Z2III4 mutant almost as active as 71III4. Other residues 
crucial for binding are conserved in the heptapeptide r gion of 
y2III4 (Asp, Ala) and in loop c where the important first Tyr 
residue is changed to the functionally equivalent His [11]. 
Therefore, only a few nucleotide substitutions give rise to a 
dramatic hange of Z1 and Z2 chain function. The sequence of 
mouse laminin 72 chain has recently available [30] and shows 
conservation of the last Ser in the heptapeptide r gion, while 
the first one is replaced by Asn as in ZIIII4, which generates 
a novel N-glycosylation site, Occupation of this site by oligo- 
saccharide may cause an inactive binding site, as presumably 
does the single Ser alone, as indicated from synthetic heptapep- 
tide studies [11], although this has not yet been studied. 
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